Twelve months from the clinic: Tales from an unlikely journey
CLASS SUMMARY
Speaker: Dr. Jeffrey Coull, President, President, Acting CEO and Founder of Chlorion Pharma
Part of the CIBC presents Entrepreneurship 101 Science and Business Do Mix series of success stories.
Dr. Jeffrey Coull discusses his experiences in building a true university spin-off in the life sciences domain.
REGISTRATION
Registration is free and required.
ENTREPRENEURSHIP 101 LECTURE SERIES
Click to find out more about the CIBC presents Entrepreneurship 101 Lecture Series.
DATE | TIME | LOCATION
April 16, 20085:30PM - 6:30PM
MaRS Centre CR-3
101 College St, Toronto
DOWNLOADS AND RESOURCES
ABOUT THE SPEAKER
A bioentrepreneur in heart and mind, Jeffrey A.M. Coull blends in-depth scientific knowledge and business acumen.Currently, he is the President, Acting CEO and Founder of Chlorion Pharma, a Montreal-based biotechnology company focused on the development of novel therapeutics for the treatment of neuropathic pain and epilepsy. Prior to founding Chlorion, Jeff spent multiple years working as a management consultant in the pharmaceutical sector (SHI Consulting), having performed strategic planning and analyses for such companies as Wyeth, Johnson and Johnson, Bristol-Myers Squibb, Sanofi-Aventis, Aspreva and Cardiome.
Jeff also worked for a boutique investment bank in Toronto. Including his work with Chlorion, he has led fundraising efforts that have culminated in financing proposals totalling $40M to date.
During his PhD studies in neuropharmacology at McGill and Laval Universities, Jeff made several seminal discoveries related to the pathophysiology of neuropathic pain. He is a principal inventor on three patent applications, which form the basis of Chlorion’s technology and therapeutic strategy.
For his research on neuropathic pain, Jeff has received several national recognitions, including the NSERC Doctoral Prize, which is awarded to the scientist with the best dissertation (natural sciences) in Canada. His work has appeared in such high impact journals as Nature and the Journal of Neuroscience, and he has contributed to pieces in the Globe and Mail and Toronto Star, among others.
